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OBJECTIVES We aimed to determine the safety and efficacy of pulmonary vein isolation (PVI) in atrial
fibrillation (AF) patients with impaired left ventricular (LV) systolic function.
BACKGROUND To date, PVI has been performed primarily in patients with normal LV function. Yet, many
AF patients have impaired LV systolic function. The outcomes of PVI in patients with
impaired LV systolic function are unknown.
METHODS We included 377 consecutive patients undergoing PVI between December 2000 and January
2003. Ninety-four patients had impaired LV function (ejection fraction [EF] 40%), and
they comprised the study group. The control group was the remaining 283 patients who had
a normal EF. End points included AF recurrence and changes in EF and quality of life
(QoL).
RESULTS Mean EF was 36% in our study group, compared with 54% in controls. After initial PVI, 73%
of patients with impaired EF and 87% of patients with normal EF were free of AF recurrence
at 14  6 months (p  0.03). In the study group, there was a nonsignificant increase in EF
of 4.6% and significant improvement in QoL. Complication rates were low and included a 1%
risk of pulmonary vein stenosis.
CONCLUSIONS Although the AF recurrence rate after initial PVI in impaired EF patients was higher than
in normal EF subjects, nearly three-fourths of patients with impaired EF remained AF-free.
Although our sample size was nonrandomized, our results suggest PVI may be a feasible
therapeutic option in AF patients with impaired EF. Randomized studies with more patients
and longer follow-up are warranted. (J Am Coll Cardiol 2004;43:1004–9) © 2004 by the
American College of Cardiology Foundationc
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aulmonary vein isolation (PVI) has become a valid treat-
ent option for patients with atrial fibrillation (AF) (1–6).
variety of PVI approaches using different ablation tech-
ologies have been reported (3,4,7–9). The vast
ajority of PVI procedures have been performed in patients
ith preserved left ventricular (LV) systolic function
1,2,6,10,11).
See page 1010
However, a significant percentage of patients with AF
ave impaired ejection fraction (EF). In one study of 163
atients with refractory AF referred for atrioventricular
ode ablation, 39% had LV systolic dysfunction (12). The
ombination of AF and structural heart disease has been
hought to be associated with a different substrate that could
esult in a higher risk of procedural complications.
Clinically, AF and heart failure are intertwined, for each
From the Center for Atrial Fibrillation, Department of Cardiovascular Medicine,
leveland Clinic Foundation, Cleveland, Ohio. This study was presented as an
bstract during the annual meeting of the American College of Cardiology, Atlanta,
eorgia, March 2002.
Manuscript received April 28, 2003; revised manuscript received August 25, 2003,hccepted September 8, 2003.an result in the other (13–15). Atrial fibrillation is generally
ccepted to be a cause of tachycardia-induced cardiomyop-
thy. Conversely, heart failure is a powerful predictor of the
evelopment of AF. After 38-year follow-up of subjects
rom the Framingham study, heart failure was associated
ith approximately a fivefold increase in the risk of
eveloping AF (16). In further analysis from the Fra-
ingham study, Wang et al. (17) recently showed that
atients with heart failure who develop AF, as well as AF
atients who develop heart failure, have increased mor-
ality. Finally, the risk of both AF and heart failure
ncreases with age (18). To date, the clinical outcomes of
VI in AF patients with impaired systolic function are
argely unknown. The objective of this study was to assess
he safety and efficacy of PVI in AF patients with
mpaired LV systolic function.
ETHODS
atient population. Between December 2000 and January
003, 377 consecutive patients were referred to our labora-
ories for AF ablation. Selection criteria for AF ablation
ncluded: 1) symptomatic AF; 2) refractoriness to anti-
rrhythmic drug therapy; and 3) no indication for open-
eart surgery. No patient with a low EF was turned down.
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March 17, 2004:1004–9 PVI in AF Patients With Impaired Systolic Functionll patients signed a written, informed consent approved by
he institutional Ethics Committee. Amiodarone was dis-
ontinued for five to six months before ablation, and other
nti-arrhythmic drugs were discontinued five half-lives be-
ore ablation. All patients underwent transthoracic echocar-
iography before undergoing the procedure. Immediately
efore the procedure, transesophageal echocardiography was
lso performed in all study patients. Of these 377 patients,
4 had impaired LV systolic function, defined as EF40%,
nd they comprised the study group. The remaining 283
atients had normal LV systolic function and served as the
ontrol group. This was a retrospective case series of AF
atients undergoing PVI.
ulmonary vein isolation. Angiogram-guided mapping
nd isolation of the pulmonary veins (PVs) were applied in
he first 56 of our study patients, as previously described (3).
n the remaining 321 patients, intracardiac echocardiogram
ICE)-guided mapping and ablation of the PV ostia were
erformed using a 10F, 64-element, phased-array ultra-
Table 1. Patient Demographics
Patien
Normal L
(n 
Women 22%
Age (yrs) 55
LA size (cm) 4.5
Ischemic, hypertensive, or idiopathic
heart disease*
22%
Valvular heart disease* 13%
Mean EF (%) 54
NYHA
Class I 95%
Class II 5%
Class III N
Class IV N
Duration of AF (yrs) 5
Type of AF
Paroxysmal 55%
Persistent 12%
Permanent 32%
Number of anti-arrhythmic drugs
tried before PVI
3
*Note that a small number of patients were counted in both c
disease, as well as valvular heart disease. Data are presented
AF  atrial fibrillation; EF  ejection fraction; LA 
Abbreviations and Acronyms
AF  atrial fibrillation
CHF  congestive heart failure
EF  ejection fraction
ICE  intracardiac echocardiogram
LV  left ventricular/ventricle
NYHA  New York Heart Association
PV  pulmonary vein
PVI  pulmonary vein isolation
QoL  quality of life
SF-36  36-Item Short-Form Health SurveyAssociation; PVI  pulmonary vein isolation.ound imaging catheter (Biosense, Diamond Bar, Califor-
ia) and a decapolar Lasso catheter (AcuNav, Acuson,
ountain View, California).
Radiofrequency energy was delivered using the cooled-tip
blation catheter (EP Technologies, Sunnyvale, California)
n all study patients. Ablation lesions were delivered in front
f the tube-like portion of the PVs. In the first 163 patients,
35°C target temperature was chosen for radiofrequency
nergy delivery through the cooled-tip catheter. At each
ite, energy was delivered for 45 s. In the remaining 214
atients, energy delivery was titrated up under ICE guid-
nce while monitoring for microbubble formation (19–21).
wo types of microbubble patterns were seen with ICE.
he type 1 pattern, which reflected early tissue overheating,
onsisted of scattered microbubbles. When the type 1
icrobubble pattern was seen, energy was titrated down by
-W decrements until the type 1 pattern subsided. The type
pattern represented an impending impedance rise and
onsisted of brisk generation of microbubbles. The goal was
o avoid type 2 microbubbles and to discontinue radiofre-
uency energy delivery if type 2 microbubbles were ob-
erved.
The goal of PVI was to abolish all PV potentials, as
easured by the circular mapping catheter. Nineteen pa-
ients with normal LV function and four patients with
mpaired LV function underwent cavotricuspid isthmus
blation for isthmus-dependent flutter at 13  7 months
efore the PVI procedure. In addition, 28 patients (10%) in
he normal LV function group and seven patients (7%) in
he impaired LV function group underwent isthmus abla-
ion during the PVI procedure for concomitant typical atrial
ith
nction
)
Patients With Impaired
LV Function
(n  94) p Value
20% (19) 0.1
57  8 0.9
3 4.7  0.8 0.06
91% (86) 0.02
16% (15) 0.1
36  8% 0.02
) None 0.001
30% (28) 0.009
68% (64) 0.005
2% (2) 0.01
6  2 0.7
) 43% (39) 0.8
13% (13) 0.9
43% (42) 0.8
2  1 0.5
ies, as they had both ischemic/hypertensive/idiopathic heart
percentage (n) of patients or mean value  SD.
trial; LV  left ventricular; NYHA  New York Heartts W
V Fu
283
(61)
 11
 0.
(62)
(36)
 3%
(268
(15)
one
one
 4
(155
(35)
(93)
 1
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PVI in AF Patients With Impaired Systolic Function March 17, 2004:1004–9utter. Four patients in the normal LV function group
nderwent ablation of non-PV foci during a second proce-
ure. No linear lines from the PV to the mitral annulus were
ade in our study population.
ollow-up and end points. Recurrence of AF, LV systolic
unction, quality of life (QoL), and complication rates were
ompared between the control and study groups. Recur-
ence of AF was assessed by a loop recorder one month after
blation; 24-h Holter monitoring at 3, 6, and 12 months;
nd 12-lead electrocardiography at 2, 3, 6, and 12 months.
onthly telephone interviews were conducted with pa-
ients. Additional monitoring with the loop recorder or
olter monitor was considered in the presence of symp-
oms. Interrogation of implanted devices was also used to
onfirm the recurrence of arrhythmias. Any episode of AF
dentified on the Holter monitor, loop recorder, or electro-
ardiogram (ECG), regardless of the duration and including
symptomatic AF, was considered a recurrence. Left ven-
ricular systolic function was compared by echocardiography
efore PVI and approximately six months after PVI. Using
he Medical Outcomes Survey 36-Item Short-Form Health
urvey (SF-36), we assessed patients both before and after
he procedure with respect to several indexes of QoL
22–24). Spiral computed tomography was performed at 10
o 12 weeks after ablation to assess for PV stenosis.
tatistical analysis. Continuous variables are expressed as
he mean  SD. Analysis of variance was used to compare
ean values between the study and control groups, and the
npaired t test was used to compare proportions between
he two groups. Categorical variables were compared by
hi-square analysis. Changes in QoL before and after
blation within the same group were compared using the
aired t test. Kaplan-Meier analysis with the log-rank test
as used to determine cumulative AF-free survival. Cox
ultivariate regression analysis was done to assess variables
redicting the recurrence of AF.
ESULTS
atient demographics are shown in Table 1. Approximately
0% of subjects were male, and the mean age was 55 years.
f the 94 patients in the study group, LV systolic dysfunc-
ion was predominantly due to ischemic heart disease (n 
3), valvular heart disease (n  15), idiopathic cardiomy-
pathy (n  4), and hypertensive heart disease (n  2).
Patients with impaired LV function had a mean EF of 36
8%, whereas patients with normal LV function had a
ean EF of 54  3% (p  0.002). The two groups differed
ignificantly with respect to their New York Heart Associ-
tion (NYHA) functional class: 68% of patients with
mpaired LV function were in class III, 30% in class II, and
% in class IV. In contrast, 95% of patients with normal LV
unction were in class I. The two groups did not differ
ignificantly with respect to other clinical characteristics,
ncluding the duration and type of AF, although there wasnonsignificant trend toward a larger left atrial size in catients with impaired LV function. Thirty (32%) of 94
atients with impaired LV function had an implantable
ardioverter-defibrillator, and 9 patients (10%) had a pace-
aker.
ecurrence of AF/atrial flutter. After a mean follow-up
f 14  5 months, the recurrence of AF was lower in
atients with normal LV function than in patients with
mpaired LV function (13% vs. 27%; p  0.03) (Fig. 1,
able 2) . The patients who remained free of AF did not
equire anti-arrhythmic drug therapy. Four patients with
ormal LV function experienced occurrence of left atrial
utter after PVI, one of whom was successfully treated with
solation of the recovered right upper and right lower PV
stia. The remaining three patients with normal LV func-
ion who developed atrial flutter are controlled in normal
inus rhythm with anti-arrhythmic drugs.
Of the patients with LV dysfunction experiencing recur-
ence, three had their AF completely suppressed with drugs
hat were previously ineffective, one experienced less fre-
uent and shorter episodes of AF, and one appeared
naffected by the procedure. One patient with depressed LV
unction experienced occurrence of left atrial flutter, which
as controlled with anti-arrhythmic medications. Twenty-
ne of the patients with LV systolic dysfunction underwent
epeat PVI and were cured. Thus, the overall cure rate in
atients with LV systolic dysfunction, after a second pro-
edure in 21 of 94 patients, was 96%. On multivariate
nalysis, age, gender, duration of AF, number of anti-
rrhythmic drugs, and left atrial size did not predict the
ecurrence of AF; only LVEF and PV ostial size were
redictors of recurrence of AF.
ulmonary vein ostia size. From ICE measurements,
atients with impaired LV systolic function had signifi-
antly larger PV ostia (average of all four veins  2.2 cm),
s compared with patients with normal LV systolic function
average of all four veins  1.4 cm) (p  0.05) (Table 3).
eft ventricular function and QoL after PVI. Figure 2
llustrates the individual changes in LVEF in patients with
mpaired LV systolic function before PVI, as compared with
ix months after PVI. Overall, LVEF increased nonsignifi-
igure 1. Kaplan-Meier analysis of our subjects. Freedom from atrial fibril-
ation (AF) after pulmonary vein isolation in patients with normal (solid line)
nd impaired (dashed line) left ventricular (LV) function (p  0.04).antly from 36.4% before PVI to 41.0% after PVI. Fifty-six
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March 17, 2004:1004–9 PVI in AF Patients With Impaired Systolic Functionf the 94 patients experienced an improvement of LVEF
fter PVI, and in these 56 patients, the mean increase in
VEF was 7.2  3%. Of the remaining 38 patients, 31 had
o change in LVEF after PVI, and three patients showed a
inimal decline. No correlation existed between improve-
ent of LVEF and type of structural heart disease, age, type
r duration of AF, or left atrial size.
Forty-three patients in the LV dysfunction group and
50 patients in the normal LV function group completed
he SF-36 questionnaire before and six months after PVI.
he patients’ QoL was significantly improved by PVI
Table 4). Six months after the procedure, patients with
mpaired LV function reported an improvement in several
reas, including general health, energy, physical functioning,
nd emotional well-being. In patients with preserved LV
unction, QoL measures improved as well.
omplications. Table 5 illustrates the complication rates.
eriprocedural stroke occurred in 3 (1%) of 283 patients
ith normal LV function and 2 (2%) of 94 patients with
mpaired LV function (p  0.08). In one patient with
mpaired LV function, the first procedure was terminated
rematurely due to pulmonary edema. A second procedure
as subsequently performed in this patient and resulted in a
ure of the patient’s AF. Severe PV stenosis, defined as
70% narrowing on the computed tomographic scan three
onths after PVI, was found in 1 (1.1%) of 94 patients with
mpaired LV dysfunction and 5 (1.7%) of 283 patients with
ormal LV function.
ISCUSSION
rimary findings. Our results suggest that PVI appears to
e safe and effective in patients with impaired LV systolic
unction. Previously reported success rates for PVI in AF
Table 2. Follow-Up Results
Patients With
LV Func
(n  28
Follow-up (months) 15 
Recurrence 13% (36
Controlled on AAD 6% (17
Successful second PVI 7% (19
Total cure off AAD (including
second procedure)
94% (26
Data are presented as the percentage (n) of patients or mean
AAD  anti-arrhythmic drugs; other abbreviations as in
able 3. Pulmonary Vein Ostia Size
Patients With
Normal LV
Function
(n  283)
Patients With
Impaired LV
Function
(n  94) p Value
ight upper PV (cm) 1.5  0.5 2.3  0.3 0.05
ight lower PV (cm) 1.4  0.2 2.1  0.2 0.05
eft upper PV (cm) 1.5  0.3 2.2  0.3 0.05
eft lower PV (cm) 1.3  0.2 2.3  0.3 0.05
ata are presented as the mean value  SD.
LV  left ventricular; PV  pulmonary vein. eave generally been for patients with normal LV function,
ith AF-free rates at five to 36 months ranging from 62%
o 86% (1,2,6,10,11). Although the AF recurrence rate at
pproximately one year was significantly higher in our
atients with impaired systolic function than in patients
ith normal LV function (27% vs. 13%, p 0.04), our 73%
uccess rate after initial PVI in patients with impaired LV
unction is well within the range of success rates cited in the
iterature for patients with normal LV systolic function.
hus, our experience indicates that patients with AF and
mpaired LV systolic function could be considered for PVI.
mprovement in LV function after PVI. Overall, the
VEF in our study group of patients improved nonsignifi-
antly by 5%, from 36% before ablation to 41% after
blation. However, 60% of our study group showed an
ncrease in LVEF after PVI, and in these responders, the
verage increase in LVEF was 7%. Previous studies have
eported LVEF to improve in patients with systolic dys-
unction after treatment of AF. In 10 patients with AF and
evere LV dysfunction initially thought to be due to idio-
athic dilated cardiomyopathy, rate control or successful
estoration of sinus rhythm appeared to result in an increase
n median LVEF from 25% to 52% (25). Other studies have
hown that in AF patients with systolic dysfunction under-
oing atrioventricular node ablation, the EF increases in
pproximately one-quarter of them (12,26,27). Although
he nonsignificant trend toward improvement in LVEF
bserved in our patients appears to be consistent with
revious studies, the small sample size limits our conclu-
ions. Our demonstrated increase in LVEF may not have
mal Patients With Impaired
LV Function
(n  94) p Value
14  6 0.1
27% (25) 0.03
3% (3) 0.1
22% (21) 0.05
96% (90) 0.2
 SD.
1.
igure 2. Changes in left ventricular ejection fraction before versus after
ulmonary vein isolation (PVI) for each individual patient with impairedNor
tion
3)
8
)
)
)
6)
valuejection fraction.
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PVI in AF Patients With Impaired Systolic Function March 17, 2004:1004–9een as dramatic as in previous studies, as our patients were
lready reasonably well rate-controlled before PVI. In pre-
ious reports, some of the increase in LVEF from treatment
f AF is likely due to achievement of adequate rate control
12).
uality of life. Previous studies have reported improve-
ents in QoL after PVI for AF (6,7). Our patients reported
n improvement in QoL after PVI for AF, consistent with
esults from previous studies. Gerstenfeld et al. (7) described
1 patients undergoing attempted PV ablation for AF.
hirty-two percent underwent mapping but no ablation
ecause of insufficient or multifocal ectopy, whereas the
emaining 68% underwent attempted ablation. Of the
ubgroup that underwent ablation, only 33% were found at
0  33 weeks to be free of AF recurrences. The authors
rospectively assessed QoL before and after ablation. The
roup that underwent mapping only did not demonstrate
ny improvement in QoL. However, the group that had
ong-term successful ablation had improvement in all six
oL measures, and the group that had AF recurrence still
ad QoL improvement in four of the six measures. More
ecently, Pappone et al. (6) described the results from a
ontrolled, nonrandomized trial of PVI and reported that
atients undergoing PVI had significant improvement in
oL, reaching normative levels, based on the SF-36 score,
hereas patients in the medical therapy group had no
hange in QoL. Our results suggest that the benefits of PVI
ith respect to QoL may extend to include patients with
mpaired LV systolic function.
iming of PV ablation. Recent data suggest that conges-
ive heart failure (CHF)-induced atrial fibrosis may be
rreversible. Shinagawa et al. (15) induced CHF in 14 dogs
able 4. Changes in Quality of Life Before Versus After Pulmon
Physical
Functioning
Role
Limitation
Due to
Physical
Health
R
Lim
D
Ph
Pro
efore PVI (normal LVEF) 28.7 8.3 2
fter PVI (normal LVEF) 96.8* 70.8* 6
efore PVI (impaired LVEF) 28.7 8.3 2
fter PVI (impaired LVEF) 90.8* 65.8* 6
p  0.05 versus before PVI.
LVEF  left ventricular ejection fraction; PVI  pulmonary vein isolation.
able 5. Complications
Patients With
Normal LV
Function
(n  283)
Patients With
Impaired LV
Function
(n  94) p Value
VA 1% (3) 2% (2) 0.7
amponade 1% (2) None 0.8
ulmonary edema leading to
procedure termination
None 1% (1) 0.8
evere PV stenosis 1.7% (5) 1% (1) 0.08
ata are presented as the percentage (n) of patients.
sCVA  cerebrovascular accident; LV  left ventricular; PV  pulmonary vein.y rapid ventricular pacing. They subsequently measured
he duration of burst-induced AF, as well as the degree of
trial fibrosis, at the end of a five-week recovery period.
hey found that reversal of CHF resulted in a decreased
uration of AF and normalization of atrial function. How-
ver, the CHF-induced atrial fibrosis was not reversible
uring this period. Their results imply that for patients with
F and LV dysfunction, atrial fibrosis occurs and may be
rreversible, thus suggesting that systolic dysfunction, as well
s AF, should be aggressively and expeditiously treated.
echnical challenges of PVI. Pulmonary vein isolation
nd ablation are technically more challenging in patients
ith an impaired LV, as these patients have elevated filling
ressures and larger PV ostia. This results in a larger area
hat potentially needs to be ablated. In addition, patients
ith LV dysfunction may have hypertrophy of the atrial
uscle, which could result in thickening of the areas
argeted for ablation. It is important to recognize that the
igh success rates in our series may reflect isolation of all
Vs and the use of ICE to facilitate PVI.
Ablation was performed using a cooled-tip ablation
atheter. Different catheter types might result in better
esults. Our group has found that the cooled-tip ablation
atheter produced slightly better results than the conven-
ional 4-mm-tip ablation catheters, although not as success-
ul as 8-mm-tip ablation catheters (3). Further prospective
tudies are required to determine the optimal catheter tip in
he subset of patients with impaired LV systolic function
nd enlarged PV ostia.
Whether the recurrence of AF reflects the presence of
on-PV foci remains unanswered. In our experience, the
ajority of patients returning for a repeat procedure showed
ecovery of conduction in one or more of the PVs ablated.
tudy limitations. This study was a retrospective case
eries of patients who underwent PVI. Randomized trials
ould strengthen the validity of the findings, as would a
arger sample size and longer-term follow-up. There could
otentially be bias in measurement of LVEF due to the lack
f blinding. However, echocardiography staff uninvolved
ith the PVI procedure interpreted the serial echocardio-
rams, so bias is unlikely in ascertaining pre- and postpro-
edural EFs. A placebo effect could have contributed to the
mprovement in the QoL measures, because each patient
ein Isolation
n
Energy
and
Fatigue
Emotional
Well-
Being
Social
Functioning Pain
General
Health
25.2 39.7 44.2 68.9 48.5
65.2* 76* 93.2* 97.2* 78.9*
25.2 39.7 44.2 68.9 48.5
61.2* 72* 93.2* 95.2* 76.9*ary V
ole
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ysical
blem
2.2
5.2*
2.2
2.2*erved as his or her own control, with QoL scores before and
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March 17, 2004:1004–9 PVI in AF Patients With Impaired Systolic Functionfter PVI being compared. However, the fact that the AF
ecurrence rate was low and EF tended to increase suggests
hat the improvement in the patients’ sense of well-being
as due to physiologic reasons.
onclusions. We report our experience with PVI in AF
atients with impaired LVEF. Although the AF-free rate of
3% after initial PVI in impaired EF subjects was lower
han that observed in normal LV function patients, this
esult compares favorably with previous series on PVI. We
lso observed a significant improvement in QoL in patients
ith impaired LV function and a nonsignificant trend
oward improvement in LV systolic function after PVI. Our
esults, although limited by the small sample size, suggest
hat PVI appears to be a safe and effective therapeutic
ption for AF patients with impaired LV systolic function.
andomized trials with larger numbers of patients and
onger follow-up are necessary to confirm our preliminary
ndings.
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